By the Doktorly editorial team · Medically reviewed by the Doktorly medical team · Last updated: 8 November 2026
Wegovy was the first semaglutide injection approved in the EU specifically for weight management – not for diabetes. That is the crucial difference from Ozempic: same active ingredient, different dose, different intended use.
On this page you will learn how treatment works, what the studies really show and what the treatment costs per month.
The EMA approved Wegovy in 2022 for adults with obesity (BMI ≥ 30) or overweight with at least one weight-related condition (BMI ≥ 27) – as an addition to dietary change and exercise. The approval was later extended: in patients with overweight and existing cardiovascular disease, Wegovy can also reduce the risk of heart attack and stroke. Adolescents aged 12 and over can be treated under certain conditions as well.
Wegovy is injected once a week under the skin. The slow build-up is deliberate, so the body can adjust to the effect:
If a step is poorly tolerated, interim levels can be held longer – this is set out in the treatment plan agreed with the medical team.
The pivotal trial STEP 1 followed nearly 2,000 participants over 68 weeks: on average, treated patients lost about 15 % of their starting weight – placebo participants just over 2 %. NEJM: STEP 1 (2021). The SELECT study additionally showed a reduction of major cardiovascular events by around 20 % in patients with overweight and pre-existing heart disease. NEJM: SELECT (2023).
As a self-payer, budget roughly 330–480 € per month, depending on dose and pharmacy. Reimbursement is possible when weight-related conditions exist and the approval criteria are met – the decision rests with each individual insurer.
Adults with obesity or overweight plus a condition such as high blood pressure, type 2 diabetes or sleep apnoea, when diet and exercise alone are not enough. Without medical clearance it is unsuitable with certain gastrointestinal, thyroid or psychiatric conditions. It is worth comparing with Mounjaro (tirzepatide) if maximum efficacy is the priority.
The duration is set by the treating medical team. Studies covered treatment periods beyond one year; long-term use is possible under regular monitoring.
In the STEP 1 extension, many participants regained part of the lost weight. That makes accompanying nutrition and exercise strategies all the more important.
No, Wegovy is injected once a week. Only the older injection Saxenda is used daily.
Yes – Rybelsus is an oral semaglutide product, but only approved for type 2 diabetes. High-dose oral formats for weight management are under review.